Open AccessCOLLABORATION AND COMMITMENT HOLD THE KEY FOR NEW DRUG DEVELOPMENT IN INDIA
Author(s) -
Madhu Dikshit,
AUTHOR_ID,
AUTHOR_ID
Publication year - 2019
Publication title -
indian drugs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.121
H-Index - 31
ISSN - 0019-462X
DOI - 10.53879/id.56.04.p0005
Subject(s) - pharmacy , medicine , government (linguistics) , business , drug development , population , drug discovery , drug , economic growth , public relations , traditional medicine , pharmacology , political science , family medicine , environmental health , biology , bioinformatics , philosophy , linguistics , economics
Dear Reader, Modern drug discovery is becoming day by day more challenging due to the stringent regulatory requirements coupled with a high rate of attrition, making drug discovery extremely cost intensive. This has brought academic institutions worldwide to the forefront to discover new drugs by finding new targets. Post-independence India had no indigenous Pharma capability and the then Government jump started the activity by setting up National laboratories such as CDRI, IICT, NCL, IIM and others under the auspices of CSIR for providing technologies to the emerging Pharma Industry that introduced very affordable quality drugs over the years enabling India to emerge as the “cradle of pharmacy” for the World. Having necessary expertise and competence in all aspects of drug discovery & development, India should aspire to introduce new drugs towards the unmet needs of our population. India has a very high incidence of fatty liver disease, type 2 diabetes, cardiovascular disorders and depression. Newly introduced Phytopharmaceutical guidelines offer us a new opportunity for making Ayurvedic drugs to be prescribed by Clinicians for local use and subsequently for global use.